<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665871</url>
  </required_header>
  <id_info>
    <org_study_id>cycdc2015-4</org_study_id>
    <nct_id>NCT02665871</nct_id>
  </id_info>
  <brief_title>Safety Study of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in Chinese Adults Aged 3 Years and Older</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chaoyang District Centre for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chaoyang District Centre for Disease Control and Prevention</source>
  <brief_summary>
    <textblock>
      This study evaluates the safety of freeze-dried live attenuated influenza vaccine for&#xD;
      intranasal administration in chinese adults aged 3 years and older.80 subjects will be&#xD;
      divided into 2 groups, including 18 years and older and 3-17 years old. Subjects in each&#xD;
      groups will randomly receive one dose of influenza vaccine or placebo in a 3:1 ratio.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the rate of adverse reactions of Live Attenuated Influenza Vaccine for Intranasal Administration</measure>
    <time_frame>3 months</time_frame>
    <description>Adverse reactions associated with vaccine will be observed in subjects after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>one dose of Influenza Vaccine in aged 18 years and older</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 18 years and older</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One dose of Influenza Vaccine in aged 3-17 year</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 3-17 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo in aged 18 years and older</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo in 10 subjects aged 18 years and older on day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo in aged 3-17 years</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo in 10 subjects aged 3-17 years on day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>one dose of Influenza Vaccine</intervention_name>
    <arm_group_label>one dose of Influenza Vaccine in aged 18 years and older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>one dose of Influenza Vaccine</intervention_name>
    <arm_group_label>One dose of Influenza Vaccine in aged 3-17 year</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo in aged 18 years and older</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo in aged 3-17 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy subjects more than 3 years&#xD;
&#xD;
          2. Guardian and/or subjects aged at least 10 subjects can be informed consent, and sign a&#xD;
             written Informed Consent Form.&#xD;
&#xD;
          3. Subjects, Guardians and his family can obey the demands of the scheme .&#xD;
&#xD;
          4. Axillary temperature less than 37℃&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with flu or infected with flu within 3 months.&#xD;
&#xD;
          2. Subjects have a vaccine allergies, allergic to any kind of composition in experimental&#xD;
             vaccine, such as eggs, ovalbumin etc.&#xD;
&#xD;
          3. Subjects have serious side effects to vaccine, such as allergy, urticaria, skin&#xD;
             eczema, dyspnea, angioneurotic edema or abdominal pain.&#xD;
&#xD;
          4. Subjects have symptoms of acute infection within a week.&#xD;
&#xD;
          5. Subjects have autoimmune disease or immune function defect, Subjects have used&#xD;
             immunosuppressive therapy, cytotoxic treatment or inhaled corticosteroids in the past&#xD;
             6 months.&#xD;
&#xD;
          6. Subjects have congenital malformations, developmental disorder or serious chronic&#xD;
             diseases( such as Down's syndrome, diabetes, Sickle cell anemia or nerve system&#xD;
             disease)&#xD;
&#xD;
          7. Subjects have asthma unstable that need emergency treatment, hospitalization,&#xD;
             intubation, oral or intravenous corticosteroid in the past 2 years.&#xD;
&#xD;
          8. Subjects have medical history or family history of convulsions, seizures,&#xD;
             encephalopathy and psychiatric disease.&#xD;
&#xD;
          9. Alienia, functional asplenia, and alienia or splenectomy in any situation.&#xD;
&#xD;
         10. Serious neurological disorders such as Green Barry syndrome.&#xD;
&#xD;
         11. Subjects have received blood products or immunoglobulin products within 3 months&#xD;
             before experimental vaccine inoculated.&#xD;
&#xD;
         12. Subjects have received other study drug in the past month or received live vaccine,&#xD;
             subunit vaccine or inactivated vaccine.&#xD;
&#xD;
         13. The indicators of blood test or urine test do not conform to the inclusion criteria.&#xD;
&#xD;
         14. Subjects have received allergy treatment in in the past 14 days.&#xD;
&#xD;
         15. Subjects are receiving anti-tuberculosis treatment.&#xD;
&#xD;
         16. Subjects have inoculated flu vaccine in the flu reason.&#xD;
&#xD;
         17. Axillary temperature is more than 37℃ before vaccination.&#xD;
&#xD;
         18. Subjects are pregnant or plan to become pregnant&#xD;
&#xD;
         19. Subjects are participate in other clinical trials.&#xD;
&#xD;
         20. Any factors unsuitable for clinical trail at the discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>safety</keyword>
  <keyword>intranasal administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

